ECSP088262A - Proteínas de fusión de albúmina - Google Patents
Proteínas de fusión de albúminaInfo
- Publication number
- ECSP088262A ECSP088262A EC2008008262A ECSP088262A ECSP088262A EC SP088262 A ECSP088262 A EC SP088262A EC 2008008262 A EC2008008262 A EC 2008008262A EC SP088262 A ECSP088262 A EC SP088262A EC SP088262 A ECSP088262 A EC SP088262A
- Authority
- EC
- Ecuador
- Prior art keywords
- albumin fusion
- fusion proteins
- vectors
- host cells
- methods
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 6
- 108010088751 Albumins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088262A true ECSP088262A (es) | 2008-05-30 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008262A ECSP088262A (es) | 2005-08-12 | 2008-03-12 | Proteínas de fusión de albúmina |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (fr) |
| JP (1) | JP2009504157A (fr) |
| KR (1) | KR20080071119A (fr) |
| AU (1) | AU2006280312A1 (fr) |
| BR (1) | BRPI0614761A2 (fr) |
| CA (1) | CA2618476A1 (fr) |
| EC (1) | ECSP088262A (fr) |
| IL (1) | IL189246A0 (fr) |
| MA (1) | MA29836B1 (fr) |
| MX (1) | MX2008001865A (fr) |
| NO (1) | NO20081233L (fr) |
| TN (1) | TNSN08064A1 (fr) |
| WO (1) | WO2007021494A2 (fr) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2841097A1 (fr) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumine et proteines hybrides g-csf |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| EP1816201A1 (fr) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée |
| EP2474318A1 (fr) * | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| WO2008033413A2 (fr) * | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| EP2423220B1 (fr) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci |
| EP2305309A2 (fr) | 2008-06-13 | 2011-04-06 | Proyecto de Biomedicina Cima, S.L. | Conjugués pour l'administration de composés biologiquement actifs |
| BRPI1004940A2 (pt) | 2009-01-16 | 2018-06-19 | Teva Pharma | composição farmacêutica |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| CA2771999A1 (fr) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Compositions de facteurs de coagulation vii et procedes de preparation et d'utilisation de celles-ci |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| US8691771B2 (en) * | 2010-05-21 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins for tissue repair |
| EP3189835B1 (fr) * | 2011-02-28 | 2018-07-25 | National Cerebral and Cardiovascular Center | Agent médical de suppression de métastase de tumeurs malignes |
| WO2012150319A1 (fr) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Variants de l'albumine |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2838833A1 (fr) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Composes pro-coagulants et leurs procedes d'utilisation |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| HRP20191920T1 (hr) | 2012-01-12 | 2020-01-10 | Bioverativ Therapeutics Inc. | Kimerni polipeptidi faktora viii i njihova uporaba |
| WO2013123457A1 (fr) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Protéines de facteur viii de recombinaison |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| EP3330283A3 (fr) | 2012-03-16 | 2018-07-11 | Albumedix A/S | Variants d'albumine |
| AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| AU2013331000B2 (en) | 2012-10-18 | 2018-04-19 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| CA2890766A1 (fr) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Variants d'albumine |
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| KR20230007555A (ko) | 2013-06-28 | 2023-01-12 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| WO2015070014A1 (fr) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Composé de fusion procoagulant |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| CA3000742A1 (fr) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Proteines therapeutiques bispecifiques pour la reparation de tissus |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| WO2018082758A1 (fr) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| CA3044838A1 (fr) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Procedes d'induction de tolerance immunitaire a des facteurs de coagulation |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| BR112019015569A2 (pt) | 2017-01-31 | 2020-03-17 | Bioverativ Therapeutics Inc. | Proteínas de fusão do fator ix e métodos para a sua produção e uso |
| WO2018193033A1 (fr) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Procédés de purification de protéines de fusion d'albumine |
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| CA3121786A1 (fr) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Utilisation de vecteurs lentiviraux exprimant le facteur ix |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| JPWO2022030580A1 (fr) * | 2020-08-06 | 2022-02-10 | ||
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| US20250333481A1 (en) * | 2022-10-11 | 2025-10-30 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein of serum albumin and physiologically-active protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841097A1 (fr) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumine et proteines hybrides g-csf |
| WO2005003296A2 (fr) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| CN102816241B (zh) * | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 CA CA002618476A patent/CA2618476A1/fr not_active Abandoned
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 EP EP06813242A patent/EP1924596A4/fr not_active Withdrawn
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Withdrawn
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/fr not_active Ceased
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008001865A (es) | 2008-04-15 |
| EP1924596A2 (fr) | 2008-05-28 |
| JP2009504157A (ja) | 2009-02-05 |
| NO20081233L (no) | 2008-05-09 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| KR20080071119A (ko) | 2008-08-01 |
| EP1924596A4 (fr) | 2009-07-29 |
| CA2618476A1 (fr) | 2007-02-22 |
| IL189246A0 (en) | 2008-08-07 |
| TNSN08064A1 (en) | 2009-07-14 |
| MA29836B1 (fr) | 2008-10-03 |
| WO2007021494A3 (fr) | 2007-07-26 |
| AU2006280312A1 (en) | 2007-02-22 |
| WO2007021494A2 (fr) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08064A1 (en) | Albumin fusion proteins | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| CY1117401T1 (el) | Πρωτεϊνες συντηξης αλβουμινης | |
| JOP20190083B1 (ar) | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها | |
| WO2005003296A3 (fr) | Proteines hybrides d'albumine | |
| ATE483027T1 (de) | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| HN2006016512A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| UY29344A1 (es) | Anticuerpos antiamiloides humanizados | |
| EA201001204A1 (ru) | Методы и композиции, в которых применяют слитые полипептиды klotho-fgf | |
| CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
| CY1110860T1 (el) | Αναστροφη μεταγραφαση τελομερασης πτηνου | |
| CR8978A (es) | Proteinas de fusion de dominio de union | |
| BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
| BR112017020986A2 (pt) | proteínas de ligação recombinantes e seu uso | |
| MX362981B (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
| PE20160718A1 (es) | Polipeptidos mutantes fgf21 | |
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| EA201391632A1 (ru) | Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды | |
| MX2024012898A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas | |
| ATE533837T1 (de) | Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen | |
| ATE439443T1 (de) | NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON | |
| UY29544A1 (es) | Tratamiento de enfermedades usando un sistema mejorado de expresión regulada |